Pfizer Asks FDA To Greenlight Covid Vaccine For Children Under 5


Pfizer has requested the Meals and Drug Administration to authorize its three-dose Covid-19 vaccine for youngsters below 5, the corporate introduced Wednesday night, a transfer that would prolong safety towards the coronavirus to the U.S.’s 18 million younger youngsters.

Key Details

The request got here simply days after Pfizer and BioNTech printed scientific trial outcomes indicating three low-dose photographs of their coronavirus vaccine produces a “robust immune response” amongst youngsters below 5.

The FDA stated it plans to evaluate the applying “as shortly as potential” however couldn’t give a timeframe for when it might be accomplished, ABC Information reported.

In April, Moderna additionally requested the FDA to grant emergency authorization for its personal coronavirus vaccine for youngsters ages 6 months to five years.

What To Watch For

At its June 14-15 assembly, the FDA’s advisory panel on vaccines will focus on the potential of extending Pfizer-BioNTech’s vaccine to youngsters ages 6 months to 4 years. The committee’s suggestions aren’t binding, however the FDA’s approval selections typically align with the panel’s.

Key Background

Pfizer and BioNTech’s emergency use authorization utility got here after months of delays. In February, the FDA requested Pfizer to submit information on the primary two doses of its three-dose course for infants and younger youngsters, in a transfer Pfizer CEO Albert Bourla stated may permit dad and mom to start vaccinating their youngsters whereas authorization of a 3rd dose was pending. Nevertheless, FDA analysis of Pfizer’s first two doses was delayed in an effort to give the corporate and regulators extra time to assemble and evaluate information. No Covid-19 vaccines are at present authorized for U.S. youngsters below 5, however the U.S. already has sufficient doses to vaccinate all 18 million youngsters in that age vary, in response to the American Hospital Affiliation.

Massive Quantity

80.3%. That’s how efficient Pfizer-BioNTech’s vaccine is at stopping Covid-19 amongst youngsters ages 6 months to 4 years, in response to analysis by Pfizer.


Pfizer and BioNTech additionally plan to submit information supporting their vaccine’s usefulness for younger youngsters to the European Medicines Company and different worldwide regulators, Pfizer stated in an announcement.

Additional Studying

“Pfizer Says Three Pictures Of Low-Dose Vaccine Generates ‘Sturdy Immune Response’ In Youngsters Below 5” (Forbes)

Full protection and stay updates on the Coronavirus

Source link

Related Articles

Back to top button
News Feed Hub